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A new approach to the development of a number of azolo-condensed azepines and diazepines has 
been proposed. The method for the synthesis of [1,3]thiazolo[3,2-b][2,4]benzodiazepine, 
benzimidazo[1,2-b][2,4]benzodiazepine and benzimidazo[1,2-b][2]benzazepine derivatives involves 
the reaction of [2-(bromomethyl)phenyl](4-chlorophenyl)methanone with 5-methyl-1,3-thiazol-2-
amine, 1H-benzimidazol-2-amine and 1,2-dimethyl-1H-benzimidazole. The formation of the 
quaternary salt of the initial diazole has been done under mild conditions in MeCN. The following 
intramolecular condensation has been realized by heating 2-amino azolium salts in AcOH or in Et3N 
as in the case of 2-methyl azolium salt. The structures of these cyclic compounds have been confirmed 
by mass spectrometry measurements, elemental analysis and NMR spectra. 
________________________________________________________________________________ 
Introduction 
The generally recognized heterocyclization 
methodsuggested by Chichibabin involves the 
reaction of -methyl and -amino pyridines with 
-halohen ketones. On the basis of the ‘principle 
of vinylogy’, this pattern was earlier done by 
using their vinylogs 1-[2-
(halogenomethyl)phenyl]methanones in order to 
produce aryl substituted pyrido[1,2-
b][2,4]benzodiazepines [1]. Compounds 
containing the benzodiazepine fragment in their 
structures appeared to be quite promising for 
biological activity tests considering their 
potential psychological and pharmaceutical 
effects [2, 3]. The majority of the well known so 
far medicinal preparations (based on 
benzodiazepine) are the derivatives of azolo-
condensed systems (Midazolam, Chlonazolam, 
Pirazolam) containing a (het)aryl substituent in 
the azepine cycle. This very fact made us try to 
prepare the azolo-condensed benzo(di)azepines 
on the basis of [2-
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(bromomethyl)phenyl](aryl)methanones. 
Making use of 2-methyl and 2-amino diazoles in 
the Chichibabin vinylogous scheme provides the 
opportunity to produce the derivatives of 
diazolo[b][2,4]benzodiazepine and 
diazolo[b][2]benzazepine systems which have 
not been extensively studied yet. At the same 
time, there are some data on the biological 
activity of the compounds mentioned above. 
Imidazo[1,2-b][2]benzazepines appeared to be 
quite effective as antiarrhythmic agents [4], for 
treating diseases and conditions of the central 
nervous system (CNS) [5,6] and antiviral 
preparations [7]. Thiazolo[3,2-
b][2,4]benzodiazepines are useful in treating 
conditions or disorders prevented by or 
ameliorated by histamine-3 receptor ligands [8], 
as inhibitors of platelet aggregation [9,10]. 
Methods for the synthesis of the 
derivatives of diazolo[b][2,4]benzodiazepines 
and diazolo[b][2]benzazepines, which have been 
described in literature, are mainly based on the 
scheme that involves the annulations of the 
diazole fragment. In a few cases concerning the 
construction of 2,4-benzodiazepine or 2-
benzazepine cycles, phthaloyl chloride [11-13], 
2-(bromomethyl)benzoate [14] and o-xylylene 
dibromide [15] have been used to produce the 
partially hydrogenated derivatives of the above 
systems. This paper describes a new method of 
azolo[b][2,4]benzodiazepines and 
azolo[b][2]benzazepine syntheses which consists 
in the interaction of [2-(bromomethyl)phenyl](4-
chlorophenyl)methanone (1) with 2-methyl and 
2-amino diazoles. 
Results and discussion 
The reaction of bromoketone 1 with 5-
methyl-1,3-thiazol-2-amine and 5-methyl-1,3,4-
thiadiazol-2-amine was done on heating the 
mixture in MeCN (Scheme 1).  
Scheme 1. The reactions with 2-aminoazoles. 
According to the NMR 1H studies, the 
product of the subsequent cyclization 2-аmino-3-
[2-(4-chlorobenzoyl)benzyl]-5-methyl-1,3-
thiazol-3-ium bromide (2) is also present in the 
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reaction mixture as early as at the quaternization 
stage of the initial amino thiazole. 10-(4-
Chlorophenyl)-2-methyl-5H-[1,3]thiazolo[3,2-
b][2,4]benzodiazepin-4-ium bromide (3) was 
isolated as a pure substance when the 
quaternization product was crystallized in acetic 
acid. Unlike thiazolium salt 2, the quaternary 
thiadiazolium salt (4) appeared to be more inert 
and it was isolated as a pure substance, and it 
failed to undergo ring formation. The reason for 
this was probably a law basicity of the amino 
group in the case of the more electron-seeking 
system of 1,3,4-thiadiazole. All attempts to form 
a ring from salt 4 by the interaction with bases 
(Et3N/acetone, K2CO3/acetone) resulted in the 
destruction of the initial salt. The structure of the 
alkylation product 4 was proved by NOE 
experimental data. Exposure to the rays at the 
frequency given by methylene group at 5.47 
ppm, the growth of the intensity of the amino 
group signal (9.96 ppm) and the doublet of the 
aromatic proton of the benzene cycle at 7.48 ppm 
(Н-6') was observed which accounted for the 
formation of 3-benzyl derivative 5-methyl-1,3,4-
thiadiazol-2-amine. 
The interaction of 1H-benzimidazol-2-
amine with bromoketone 1 in MeCN leads to the 
formation of large number by-products that 
interfere with the purification of the final product 
of the reaction. The more yielding transformation 
was done in acetone in the presence of potash at 
room temperature and resulted in tertiary amine 
(5). Intramolecular condensation of the base was 
carried out on heating it in acetic acid, the 
derivative of 12H-benzimidazo[1,2-
b][2,4]benzodiazepine (6) being produced. On 
heating above 200 oC substance 5, formed a ring 
producing 6, therefore, it made impossible to 
determine the melting point of starting amine 5. 
Alkylation of 1,2-dimethylbenzimidazole 
with the help of bromoketone 1 in acetone at 
room temperature caused the formation of 
quaternary salt 7 with high yield. Substance 7 
appeared to be quite stable to the heating in 
AcOH, whereas heating it with bases resulted in 
the intramolecular condensation and production 
of 7-(4-chlorophenyl)-5-methyl-5H,12H-
benzimidazo[1,2-b][2]benzazepin-13-ium 
bromide (8) (Scheme 2). 
 
Scheme 2. The reaction with 1,2-dimethylbenzimidazole. 
The structures of the cyclization products 
3, 6, 8 were confirmed by mass-spectrometry 
measurements, elemental analysis and by 
comparing their spectra to those of the earlier 
prepared salts of 11H-pyrido[1,2-
b][2,4]benzodiazepinium [1] and 5,10-
dihydroazepino[2,1-b]benzimidazolium [16]. 
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The characteristic features of azolo-condensed 
diazepines 3, 6 and azepine 8 are their high rates 
of the conformational transformations. This was 
supported by the coalescence and the pronounced 
widening of the proton signals in the methylene 
groups in NMR 1H spectra (at 20 oC) which 
recorded as highly wide double-proton singlets in 
the case of substance 3 in the range of 5.4–6.9 
ppm. 
Conclusions 
Consequently, on the basis of ‘principle 
of vinylogy’ we have proposed a new way of 
construction of 2,4-benzodiazepine and 2-
benzazepine cycles on 1,3-diazoles. The method 
consists in using o-(bromomethyl)benzophenone 
derivatives in the scheme proposed by 
Chichibabin. It allows producing aryl substituted 
derivatives of a series of azolo-condensed hetero 
systems such as 5H-[1,3]thiazolo[3,2-
b][2,4]benzodiazepine, 12H-benzimidazo[1,2-
b][2,4]benzodiazepine and 5H,12H-
benzimidazo[1,2-b][2]benzazepine which have 
not earlier been affordable. 
Experimental part 
1H NMR were recorded on the Varian 
VXR-400, internal standard was TMS. IR spectra 
were recorded on the PerkinElmer Spectrum BX. 
Elemental analyses were made on the universal 
analyzer vario MikroCube, for the determination 
of halogens the Sheninger method is used. 
Melting points were determined on a Tile heating 
instrument. A check on the purity of the obtained 
compounds was affected by the GLC mass 
spectrometric method on an Agilent 1100 Series 
instrument, with an Agilent LC/MSD SL 
selective detector (samples were introduced in a 
matrix of CF3CO2H, ionization by EI). [2-
(Bromomethyl)phenyl](4-
chlorophenyl)methanone 1 was prepared as 
reported [17]. All other chemicals and solvents 
are commercially available and were used 
without further purification. 
 
10-(4-Chlorophenyl)-2-methyl-5H-
[1,3]thiazolo[3,2-b][2,4]benzodiazepin-4-ium 
bromide 3.  
The mixture of 1 g (3.2 mmol) of [2-
(bromomethyl)phenyl](4-
chlorophenyl)methanone 1 and 1.08 g (3.5 
mmol) of 5-methyl-1,3-thiazol-2-amine in 10 mL 
of anhydrous MeCN was heated for 8 h at 60 оС, 
allowed to stand over 24 h at room temperature.  
The precipitate was filtered off, washed with 
acetone, and presented a mixture of 2-amino-3-
[2-(4-chlorobenzoyl)benzyl]-5-methyl-1,3-
thiazol-3-ium bromide 2 and 10-(4-
chlorophenyl)-2-methyl-5H-[1,3]thiazolo[3,2-
b][2,4]benzodiazepin-4-ium bromide 3 (1:1). 
The resulting mixture was dissolved in 10 ml of 
AcOH and boiled for 3 hours. The solvent was 
evaporated and 10 ml of acetone was added to the 
residue. The precipitate was filtered off, washed 
with acetone, recrystallized from MeOH to 
afford colorless solid of 3. 
Yield: 0.62 g, 48%; mp > 300 oC 
(MeOH); 1H NMR (400 MHz, DMSO-d6, J Hz): 
 8.16 (1Н, s, Н-3), 7.92 (2Н, d, 3J = 8.5, Н-2', 
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Н-6'), 7.88 (1Н, d, 3J = 8.0, Н-7), 7.75 (1Н, d, 3J 
= 8.0, Н-6), 7.70 (2Н, d, 3J = 8.5, Н-3',  Н-5'), 
7.64 (1Н, t, 3J = 8.0, Н-8), 7.49 (1Н, d, 3J = 8.0, 
Н-9), 6.85 (1H, broad. s, C(5)HAHB), 5.50 (1H, 
broad. s, C(5)HAHB), 2.58 (3Н, s, СН3) ppm; MS 
(CI): m/z = 325.8 ([М-Br]+, 100%), 327.7 (28%); 
Analysis (calcd, found)%: C (53.28, 53.34); H 
(3.48, 3.50); N (6.90, 6.92); S (7.90, 7.92). 
2-Аmino-3-[2-(4-chlorobenzoyl)benzyl]-
5-methyl-1,3-thiazol-3-ium bromide 2 (50% in 
mixture). IR (KBr):  3136 (NH2), 1651 (C=O) 
cm-1;  1H NMR (400 MHz, DMSO-d6, J Hz):   
9.70 (2H, broad. s, NH2), 7.87 (1H, d, 3J = 8.0, 
H-6'), 7.77 (2H, d, 3J = 8.5, Н-2'', Н-6''), 7.58 
(2Н, d, 3J = 8.5, Н-3'',  Н-5''), 7.51 (2H, m, H-4', 
H-5'), 7.18 (1H, d, 3J = 8.0, H-3'), 7.07 (1H, s, H-
4), 5.45 (2H, s, CH2), 2.21 (3H, s, CH3). 
 
2-Amino-3-[2-(4-chlorobenzoyl)benzyl]-
5-methyl-1,3,4-thiadiazol-3-ium bromide 4. 
The mixture of 1.08 g (3.2 mmol) of 
methanone 1 and 0.40 g (3.5 mmol) of 5-methyl-
1,3,4-thiadiazol-2-amine in 10 mL of anhydrous 
MeCN was heated for 8 h at 60 оС, allowed to 
stand over 24 h at room temperature.  The 
precipitate was filtered off, washed with acetone, 
recrystallized from MeNO2 to afford colorless 
solid of 4. 
Yield: 0.48 g, 35%; mp 231–233 oC 
(MeNO2); IR (KBr):  3095 (NH2), 3013 (NH2), 
2899, 1664 (C=O), 1628, 1579, 1550, 1264, 
1090, 923, 737 cm-1; 1H NMR (400 MHz, 
DMSO-d6, J Hz):  7.69–7.60 (5Н, m, Н-3', Н-
5', Н-6', Н-2'', Н-6''), 7.52 (1Н, t, 3J = 8.0,  Н-4'), 
7.46 (2Н, d, 3J = 8.5, Н-3'', Н-5''), 9.96 (2Н, 
broad. s, NH2), 5.47 (2Н, s, СН2), 2.29 (3Н, s, 
СН3) ppm; MS (CI): m/z = 344.9 ([М-Br]+, 
100%), 346.7 (30%); Analysis (calcd, found)%: 
C (48.07, 48.10); H (3.56, 3.60); N (9.89, 9.86); 
S (7.55, 7.58). 
 
{2-[(2-Amino-1H-benzimidazol-1-
yl)methyl]phenyl}(4-chlorophenyl)methanone 5.  
To a solution of 1.08 g (3.2 mmol) of  
methanone 1 in 20 mL of anhydrous acetone was 
added 0.6 g of K2CO3 and stired the mixture for 
3 hours at room temperature. The solvent was 
evaporated in vacuo, the residue was washed 
with water. Solid recrystallized from i-PrOH to 
afford colorless solid of 5. 
Yield: 0.86 g, 74%; mp > 210 oC 
(decomp., i-PrOH); IR (KBr):  3369 (NH2), 
3328 (NH2), 3059, 1669 (С=О), 1649, 1587, 
1555, 1460, 1295, 1269, 1243, 1091, 930, 739 
cm-1; 1H NMR (400 MHz, DMSO-d6, J Hz):  
7.77 (2Н, d, 3J = 8.5, Н-2'', Н-6''), 7.46 (2Н, m, 
Н-4, Н-6), 7.38 (1Н, t, 3J = 8.0, Н-5), 7.12 (1Н, 
d, 3J = 8.0, Н-4'), 6.92 (1Н, t, 3J = 8.0, Н-6''), 
6.85–6.75 (3Н, m, Н-3, Н-5'', Н-7''), 6.47 (2Н, 
broad. s, NH2), 5.36 (2Н, s, СН2) ppm; 13С NMR 
(100.7 MHz, DMSO-d6): 196.5 (C=O), 155.9 
(C-2), 143.6, 136.4, 134.8, 132.5, 132.4 (2C), 
132.1 (2C), 130.4, 129.4 (4C), 127.4 (2C), 121.3, 
118.8, 115.5, 108.3, 43.7 (CH2) ppm; MS (CI): 
m/z = 362.7 ([М+Н]+, 100%), 364.7 (29%); 
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Analysis (calcd, found)%: C (69.71, 69.45); H 
(4.46, 4.50); Cl (9.80, 9.82); N (11.61, 11.57). 
 
7-(4-Chlorophenyl)-12H-
benzimidazo[1,2-b][2,4]benzodiazepine 6.  
А solution of 0.72 g (2.0 mmol) of {2-[(2-
amino-1H-benzimidazol-1-
yl)methyl]phenyl}(4-chlorophenyl)methanone 5 
in 20 ml of AcOH was boiled for 3 hours. The 
solvent was evaporated and 10 mL of acetone 
was added to the residue. The precipitate was 
filtered, washed with a small amount of acetone, 
recrystallized from МеОН to afford yellow solid 
of 6. 
Yield: 0.35 g, 51%; mp 293–295 oC 
(decomp., MeOH); IR (KBr):  3059, 1581, 
1556, 1408, 1091, 747, 729 cm-1; 1H NMR (400 
MHz, DMSO-d6, J Hz):  7.86 (2Н, d, 3J = 8.5, 
Н-2', Н-6'), 7.83 (1Н, t, 3J = 8.0, Н-10), 7.75 (1Н, 
d, 3J = 8.0, Н-11), 7.64 (3Н, m, Н-4, Н-3', Н-5'), 
7.55 (1Н, d, 3J = 8.0, Н-1), 7.45 (1Н, d, 3J = 8.0, 
Н-9), 7.34 (1Н, d, 3J = 8.0, Н-8), 7.24 (1Н, t, 3J 
= 8.0, Н-3), 7.17 (1Н, t, 3J = 8.0, Н-2), 5.42 (2Н, 
broad. s, CH2) ppm; MS (CI): m/z = 344.7 
([М+H]+, 100%), 346.8 (30%); Analysis (calcd, 
found)%: C (73.36, 73.40); H (4.10, 4.08); Cl 
(10.31, 10.33);  N (12.22, 12.20). 
 
1-[2-(4-Chlorobenzoyl)benzyl]-2,3-
dimethyl-3H-benzimidazol-1-ium bromide 7.  
To a solution of 0.8 g (5.5 mmol) of 1,2-
dimethyl-1H-benzimidazole in 10 mL of 
anhydrous acetone was added 1.55 g (5.0 mmol) 
of methanone 1 and allowed to stand over 72 h at 
room temperature. The formed precipitate was 
filtered off, washed with acetone, recrystallized 
from MeNO2 to afford colorless solid of 7. 
Yield: 1.44 g, 63%; mp 261–262 oC 
(MeNO2); IR (KBr):  3008, 2868, 1656 (С=О), 
1583, 1474, 1278, 1091, 926, 775, 752 cm-1; 1H 
NMR (400 MHz, DMSO-d6, J Hz):  7.93 (1Н, 
d, 3J = 8.0, Н-6), 7.65–7.53 (10Н, m, Н-3–Н-5, 
Н-4'–Н-5',  Н-2''–Н-6''), 7.25 (1Н, d, 3J = 8.0, Н-
6'), 5.92 (2Н, s, СН2), 3.96 (3Н, s, NСН3), 2.84 
(3Н, s, ССН3) ppm; 13С NMR (100.7 MHz, 
DMSO-d6):  196.3 (C=O), 153.5 (C-2), 139.4, 
136.8, 135.5, 134.0, 132.3 (3C), 132.2, 131.4, 
130.4, 129.4 (3C), 128.7, 126.9, 126.8, 113.7, 
113.5, 47.3 (CH2), 32.6 (N-CH3), 11.5 (2-CH3) 
ppm; MS (CI): m/z = 375.9 ([М-Br]+, 100%), 
377.8 (28%); Analysis (calcd, found)%: C 
(60.61, 60.66); H (4.42, 4.39); N (6.15, 6.14). 
 
7-(4-Chlorophenyl)-5-methyl-5H,12H-
benzimidazo[1,2-b][2]benzazepin-13-ium 
bromide 8.  
To a solution of 0.46 g (1.0 mmol) of 
bromide 7 in 20 mL of i-PrOH was added 0.5 mL 
of Et3N. The reaction mixture was boiled for 3 
hours, the precipitate was filtered off, washed 
with acetone to afford colorless solid of 8. 
Yield: 0.34 g, 77%; mp > 300 oC 
(MeOH); IR (KBr):  3008, 1597, 1566, 1482, 
1091, 775 cm-1; 1H NMR (400 MHz, DMSO-d6, 
J Hz):  8.49 (1Н, d, 3J = 8.0, Н-1), 8.01 (1Н, d, 
3J = 8.0, Н-4), 7.95 (1Н, d, 3J = 8.0, Н-11), 7.75–
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7.63 (8Н, m, Н-2, Н-3, H-6, Н-10, Н-2'–Н-6'), 
7.45 (1Н, t, 3J = 8.0, Н-9), 7.11 (1Н, d, 3J = 8.0, 
Н-8), 5.71 (2Н, broad. s, CH2), 4.16 (3Н, s, СН3) 
ppm; 13С NMR (100.7 MHz, DMSO-d6):  155.5 
(C-5a), 146.8, 139.9, 136.8, 136.4, 135.6, 133.4, 
132.3, 132.2 (2C), 131.7, 130.8, 129.8, 129.6, 
129.5 (2C), 127.3, 127.1, 113.8, 113.5, 111.3, 
47.9 (CH2), 32.8 (CH3) ppm; MS (CI): m/z = 
357.9 ([М-Br]+, 100%), 359.8 (30%); Analysis 
(calcd, found)%: C (63.10, 63.15); H (4.14, 
4.17); N (6.40, 6.42). 
Conclusions 
The conclusions section should come in 
this section at the end of the article, before the 
acknowledgements. This should state clearly the 
main conclusions of the research and give a clear 
explanation of their importance and relevance. 
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